Archives
-
Methyl-β-cyclodextrin: Identity and Evidence Scope
2026-10-13
Methyl-β-cyclodextrin, also called methyl beta cyclodextrin, is listed by APExBIO as a methylated β-cyclodextrin derivative for conceptual studies of membrane lipids. Because no matched research paper is available, the evidence supports product identity and intended research scope only—not study-specific mechanisms, outcomes, comparisons, or practical recommendations.
-
Early Pheromone Signals and Adult Neurodegeneration
2026-10-12
Peng et al. report that early developmental perception of two C. elegans pheromones can reshape neural signaling and accelerate later neurodegeneration. The study supports a mechanistic model involving ASK and ASI sensory neurons, AIA interneurons, insulin-like signaling, and neuronal autophagy, while remaining limited by its single-organism model and uncertain relevance to human disease. HyperFusion™ high-fidelity DNA polymerase is discussed only as a separate supplier-described molecular tool, not as a reagent used or evaluated in the study.
-
SNS-032 and SARS-CoV-2: Evidence Gaps
2026-10-12
The supplied evidence supports a host-factor role for vesicular transport and a CDKI-73-sensitive SARS-CoV-2 release phenotype, but it does not show that SNS-032 (BMS-387032) has the same activity. The main gaps concern compound identity, assay interpretation, cell-model applicability, and the difference between viral nucleic-acid measurements and infectious-virus outcomes.
-
GS967 and the Aging Heart: Late Sodium Current
2026-10-10
GS967 is a research-use cardiac late sodium current inhibitor used to interrogate how persistent Nav1.5 activity may influence ventricular repolarization, calcium handling, relaxation, and arrhythmia phenotypes. This overview separates supplier-reported pharmacology from findings in a 2024 aging-heart study and outlines the evidence strength, conceptual applications, and limits of translating genetic and animal-model results to human disease.
-
Separating Growth Inhibition from Cell Death
2026-10-09
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability when evaluating anticancer drug responses. Its central finding is that growth inhibition and cell death often occur together but differ in magnitude and timing, making endpoint selection essential for interpreting drug activity.
-
Bergenin, PPARγ, and γδT17 Cells in Psoriasis
2026-10-09
A 2026 Phytomedicine study links bergenin to a PPARγ–PROX1 pathway that suppresses pathogenic γδT17 activity, fatty acid oxidation, and IL-17A production in psoriasis models. Its main contribution is a mechanistic connection between ubiquitin-mediated protein turnover, immune-cell metabolism, and inflammatory chromatin regulation, although the evidence remains preclinical.
-
LG 101506 and RXR Signaling: Evidence to Hypothesis
2026-10-08
Explore how LG 101506 can support rigorous RXR signaling pathway research without overstating what current evidence proves. This article connects RXR biology with the RBMS1–B4GALT1–PD-L1 mechanism in triple-negative breast cancer while defining testable questions, evidence boundaries, and translational limitations.
-
Amyloid Beta-Peptide (1-40): Research Context
2026-10-08
A source-grounded overview of Aβ40 biology, microglial signaling, evidence strength, and research limitations.
-
FOXM1–ERα Network in Female Lung Adenocarcinoma
2026-10-07
The reference preprint integrates transcriptomic, survival, immune, and cellular analyses to examine FOXM1 in female lung adenocarcinoma (LUAD). Its proposed FOXM1–miR-204-5p–ERα framework is an important hypothesis-generating contribution, although the evidence remains primarily computational and in vitro rather than clinically validated.
-
H 89 2HCl in cAMP/PKA Signaling Research
2026-10-07
H 89 2HCl is a widely used pharmacological tool for studying PKA-linked signaling, but its cellular selectivity is narrower than its biochemical reputation may suggest. This overview places the compound in the context of dopamine-regulated osteoclastogenesis, compares evidence types, and defines key limitations for interpreting pathway experiments.
-
Sisomicin vs. Tobramycin in Clinical Isolates
2026-10-06
Stewart and Bodey evaluated sisomicin against 565 clinical isolates and compared its in vitro activity with gentamicin, Tobramycin, amikacin, butirosin, and kanamycin. The study found broad activity against most Gram-negative bacilli, while its resistance comparisons showed that gentamicin- and Tobramycin-resistant isolates were generally resistant to sisomicin, with amikacin retaining activity against many of these strains.
-
Perospirone: Receptor Pharmacology and Kv1.5 Evidence
2026-10-06
Perospirone, also known as SM-9018 free base, is primarily studied as a serotonergic and dopaminergic antipsychotic agent. A 2025 study adds evidence that it inhibits vascular voltage-gated potassium currents in rabbit coronary arterial smooth muscle cells, while leaving important questions about subtype selectivity, exposure relevance, and clinical translation unresolved.
-
FDXR Nuclear Translocation and AKT Phosphorylation
2026-10-05
A 2026 Biochemical Journal study shows that mitochondrial ferredoxin reductase can enter the nucleus under cellular stress and identifies AKT-dependent phosphorylation near a bipartite nuclear localization signal as an important regulatory mechanism. The findings expand FDXR biology beyond mitochondrial metabolism and provide a framework for studying phosphorylation-dependent mitochondria–nucleus communication.
-
Influenza M mRNA Export Through NS1-BP and NXF1
2026-10-05
A 2024 Journal of Biological Chemistry study proposes that influenza A virus M1 and M2 mRNAs evade NS1-mediated host mRNA export inhibition through an NS1-BP–NXF1 pathway. The findings connect viral RNA processing, TREX-2-associated export, and nuclear pore complex docking, refining the mechanistic view of how essential viral transcripts reach the cytoplasm.
-
Bergenin Targets γδT17 Cells in Psoriasis
2026-10-04
A 2026 Phytomedicine study identifies a PPARγ–PROX1 ubiquitination pathway through which bergenin suppresses pathogenic γδT17-cell activity and IL-17A production in psoriasis models. The work connects immune-cell targeting with fatty acid oxidation and chromatin regulation, while its preclinical design leaves clinical efficacy and broader transferability unresolved.